- Conditions
- Parkinson's Disease
- Interventions
- Exenatide
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 40 Years to 77 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 578
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hypoglycemia
- Interventions
- Glucagon
- Drug
- Lead sponsor
- Xeris Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Walnut Creek, California
- Conditions
- Weight Loss, Weight Gain, Obesity
- Interventions
- Intensive lifestyle change therapy, Tirzepatide
- Behavioral · Drug
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin glargine, Liraglutide, Metformin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 978 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LY3025876, Placebo, Liraglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Chula Vista, California • Orange, California • Miami, Florida + 1 more
- Conditions
- Type 2 Diabetes, Gastric Banding
- Interventions
- Liraglutide, Orlistat, Liraglutide + Orlistat
- Drug
- Lead sponsor
- East Carolina University
- Other
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 11
- States / cities
- Cooper City, Florida • West Palm Beach, Florida • Skokie, Illinois + 6 more
- Conditions
- Obesity & Overweight, Diabetes (DM)
- Interventions
- Glucagon-Like Peptide-1 Agonist (GLP-1)
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Wrinkle
- Interventions
- Skinvive
- Device
- Lead sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
- Other
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
- Interventions
- Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
- Drug · Other · Dietary Supplement + 1 more
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cardiovascular Kidney Metabolic Syndrome, Type 2 Diabetes
- Interventions
- Exercise is Medicine (EIM), Culinary Education, Food is Medicine, Nutrition Counseling, Participant Website
- Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Columbus, Ohio • Upper Arlington, Ohio
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
- Conditions
- Obesity
- Interventions
- Incretin-based therapies (GLP-1 and GLP-1/GIP)
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 125,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Obesity and Overweight, Binge Eating Disorder
- Interventions
- Tirzepatide, Lisdexamfetamine Dimesylate, Guided self-help cognitive behavioral therapy, Placebo (oral), Placebo (injection)
- Drug · Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 1 Diabetes
- Interventions
- REMD-477, Placebo
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Anaheim, California • Fresno, California + 27 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- tirzepatide, Dulaglutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 35
- States / cities
- Mobile, Alabama • Anaheim, California • Fresno, California + 30 more
- Conditions
- HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome
- Interventions
- Liraglutide
- Drug
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques
- Interventions
- Gastric Fundal Mucosal Ablation (GFMA)
- Device
- Lead sponsor
- Dr. Christopher McGowan
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cary, North Carolina
- Conditions
- Obesity, Overweight and Obesity, Overweight
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Fresno, California + 37 more
- Conditions
- Type2Diabetes, ASCVD
- Interventions
- SGLT2 inhibitor, GLP-1 receptor agonist
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 6,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 36
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more
- Conditions
- Hypoglycemia
- Interventions
- dasiglucagon, placebo, GlucaGen HypoKit
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Escondido, California • New Haven, Connecticut • Indianapolis, Indiana